Effect of Rp diastereoisomer of adenosine 3',5' cyclic-monophosphothioate on the cAMP-Dependent relaxation of smooth muscle

Life Sciences

Volumn 61, Issue 9, 1997, Pages 869-880

  Pérez Vallina, Jose R ^a   Revuelta, M Pilar ^a   Cantabrana, Begoña ^a   Hidalgo, Agustin ^a,b  

^a Faculty de Medicina   (Spain)

^b Laboratorio de Farmacologia   (Spain)

Author keywords

8 BrcAMP; cAMP dependent protein kinase; Histamine; Papaverine; Rp cAMPS; Smooth muscle contraction

Indexed keywords

8 BROMO CYCLIC AMP; 8 BROMO CYCLIC GMP; ADENOSINE 3',5' PHOSPHOROTHIOATE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EDETIC ACID; ESTRADIOL BENZOATE; FORSKOLIN; HISTAMINE; PAPAVERINE; POTASSIUM CHLORIDE; PROTEIN KINASE; ROLIPRAM; VANADIC ACID; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG ANTAGONISM; FEMALE; NONHUMAN; RAT; SMOOTH MUSCLE RELAXATION; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS CONTRACTILITY;

ANIMALS; CYCLIC AMP; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FORSKOLIN; HISTAMINE; MUSCLE RELAXATION; PAPAVERINE; PHOSPHODIESTERASE INHIBITORS; POTASSIUM CHLORIDE; PYRROLIDINONES; RATS; RATS, WISTAR; ROLIPRAM; STEREOISOMERISM; THIONUCLEOTIDES; UTERINE CONTRACTION; UTERUS; VANADATES; VINCA ALKALOIDS;

ANIMALIA;

EID: 0343052872     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00589-4     Document Type: Article

References (52)

1. K.J. MURRAY, Pharmac. Ther. 47 329-345 (1990).
2. S. WRAY, Am. J. Physiol. 264 (Cell Physiol 33), C1-C18 (1993).
3. R.L. JARVEST, G. LOWE, J. BARANIAK and W.J. STEC, Biochem. J. 203 461-470 (1982).
4. P.J.M. VAN HAASTERT, R. VAN DRIEL, B. JASTORFF, J. BARANIAK, W.J. STEC and R.J.W. De WIT, J. Biol. Chem. 259 10020-10024 (1984).
5. L.H. PARKER BOTELHO, J.D. ROTHERMEL, R.V. COOMBS and B. JASTORFF, Meth. Enzimol. 159 159-172 (1988).
6. J.D. ROTHERMEL, B. JASTORFF and L.H. PARKER BOTELHO, J. Biol. Chem. 259 8151-8155 (1984).
7. B.V.L. POTTER, Transmembrane signalling. Intracellular messengers and implications for drug development, S.R. Nahorski (Ed) 207-239 John Wiley and Sons Ltd. London (1990).
8. M.J. LEROY, I. CEDRIN, M. BREUILLER, Y. GIOVAGRANDI and F. FERRE, Biochem. Pharmacol. 38 9-15 (1989)
9. M. SALAICES, A. de GREGORIO and J. MARIN, Gen. Pharmacol. 16 633-636 (1985)
10. Y. NOMURA, Y. KITAMURA, M. TOHDA and Y. TOKUMITSU, Med. Res. Rev. 13 1-60 (1993).
11. A.I. FERNANDEZ, B. CANTABRANA and A. HIDALGO, Gen. Pharmacol. 23 291-296 (1992).
12. J.R. PÉREZ VALLINA, L. MENÉNDEZ, B. CANTABRANA and A. HIDALGO, Pharm. Sci. 1 185-187 (1995)
13. B. CANTABRANA, J.R. PÉREZ VALLINA, L. MENÉNDEZ and A. HIDALGO, Life Sci. 57 1333-1341 (1995).
14. H. KARAKI and G. WEISS, Life Sci, 42 111-122 (1988).
15. T. GODFRAIND, Pharmac. Ther, 64 37-75 (1994).
16. A.L. RUZYCKY, D.J. CRANKSHAW and D.J. TRIGGLE, Can. J. Physiol. Pharmacol, 65 2085-2092 (1987).
17. A.K. GROVER, C.N. KWAN and E.E. DANIEL, Am. J. Physiol, 240 C175-C182 (1981)
18. K.S. HWANG and C. VAN BREEMEN, Eur. J. Pharmacol, 134 155-162 (1987).
19. J.F. KRALL, J. L. SWENSEN and S.G. KOREMAN, -Biochem. Biophys. Acta, 448 578-588 (1976).
20. E. RUBIO, L. ESTAÑ, F.J. MORALES-OLIVAS, & M.I. MARTÍNEZ-MIR, J. Auton. Pharmacol. 13 395-402 (1993).
21. S.H. FRANCIS and J.D. CORBIN, Annu. Rev. Physiol. 56 237-272 (1994).
22. K.B. SEAMON and J.W. DALY, Adv. Cyclic Nucleotide Protein Phosphorylation Res, 20 1-150.
23. S. LINDGREN and K-E ANDERSSON, Gen. Pharmacol. 22 617-624 (1991).
24. D.H. SOLOMON, C.A. O'BRIAN and I.B. WEINSTEIN, FEBS Lett. 190 342-344 (1985).
25. M.P. REVUELTA, B. CANTABRANA and A. HIDALGO, Gen. Pharmacol. (In press).
26. R.A. JOHNSON, S.H. YEUNG, D. STÜBNER, M. BUSHFIELD and I. SHOSHANI, Mol. Pharmacol. 35 681-688 (1989).
27. R.A. JOHNSON and Y. SALOMON, Meth. Enzymol. 195 3-29 (1991).
28. A. LAURENZA and K.B. SEAMON, Meth. Enzimol. 195 52-65 (1991).
29. A. LAURENZA, E.M. SUTKOWSKI and K.B. SEAMON, Trends Pharmacol. Sci. 10 442-447 (1989).
30. D.D. SMITH and J.M. MARSHALL, Eur. J. Pharmacol. 122 29-35 (1986)
31. L. DO KHAC, A. MOKHTARI and S. HARBON, J. Pharmacol. Exp. Ther. 239 236-242 (1986)
32. H. IZUMI and T. KISHIKAWA, Br. J. Pharmacol. 76 463-471 (1982).
33. J.A. BEAVO, Physiol. Rev. 75 725-748 (1995)
34. C.D. NICHOLSON, R.A.J. CHALLIS and M. SHAHID, Trends Pharmacol. Sci. 12 19-27 (1991).
35. S. KANEKO, M. SUGIMURA, T. INOUE and M. SATOH, Eur. J. Pharmacol. 207 119-126 (1991).
36. P. MOLNAR and S.L. ERDÓ, Eur. J. Pharmacol. 273 303-306 (1995).
37. M.J. LEROY, I. CEDRIN, M. BREUILLER, Y. GIOVAGRANDI and F. FERRE, Biochem Pharmacol. 38 9-15 (1989).
38. A. TOMKINSON, J-A. KARLSSON and D. RAEBURN, Br. J. Pharmacol. 108 57-61 (1993).
39. T. MÜLLER, P. ENGELS and J.R. FOZARD, Trends Pharmacol. Sci. 17 294-298 (1996).
40. W.F. JACKSON, Pharmacology 52 226-234 (1996).
41. T.M. LINCOLN, T.L. CORNWELL and A.E. TAYLOR, Am. J. Physiol. 258 C399-497 (1980)
42. M. NAKAZAWA and S. IMAI, Eur. J. Pharmacol. 253 179-181 (1994).
43. R.A. WORD, M.L. CASEY, K. KAMM and J.T. STULL, Am. J. Physiol. 260 C861-C867 (1991).
44. J. SANDIRASEGARANE and V. GOPALAKRISHNAN, Life Sci. 56 169-174 (1995).
45. J. DI SALVO, L.A. SEMENCHUK and J. LAUER, Arch. Biochem. Biophys. 304 386-391 (1993).
46. P. AUSINA, J-P. SAVINEAU, F.M. PINTO, J.D. MARTIN and L. CANDENAS, Eur. J. Pharmacol. 312 309-318 (1996).
47. P.J. SILVER and D.S. KRAFTE, Biochemistry of smooth muscle contraction , M. Bárány (Ed) 367-376 Academic Press Inc New York (1996).
48. N.L. HARRISON and N.A. LAMBERT, Neurosci. Lett. 105 137-142 (1989)
49. M.K. TICKU and A.K. MEHTA, Mol. Pharmacol. 38 719-724 (1990).
50. N.A. LAMBERT and N.L. HARRISON, J. Pharmacol. Exp. Ther. 255 90-94 (1990)
51. B. YUSTA, J-ORTIZ-CARO, A. PASCUAL and A. ARANDA, J. Neurochem. 51 1808-1818 (1988).
52. M. BOUTJDIR, P-F MÉRY, R. HANF, A. SHRIER and R. FISCHMEISTER, Mol. Pharmacol. 38 758-765 (1990).